Eflornithine Plus Lomustine Extends Progression-Free and Overall Survival in Recurrent IDH‑Mutant Grade 3 Astrocytoma — Results from STELLAR Phase III
The STELLAR phase III trial found that eflornithine added to lomustine doubled PFS and significantly improved OS in patients with recurrent IDH‑mutant grade 3 astrocytoma after radiotherapy and temozolomide, with increased but manageable myelosuppression and hearing toxicity.